Login / Signup

Treatment with golimumab or infliximab reduces health resource utilization and increases work productivity in patients with ankylosing spondylitis in the QUO-VADIS study, a large, prospective real-life cohort.

Pascal ClaudepierreFilip Van den BoschPiercarlo Sarzi-PuttiniNathan VastesaegerMarinella GovoniSumesh Kachroo
Published in: International journal of rheumatic diseases (2019)
In patients with AS newly treated with GLM or IFX for 6 months, HCRU was reduced and work productivity and activity increased.
Keyphrases
  • ankylosing spondylitis
  • rheumatoid arthritis
  • disease activity
  • climate change
  • healthcare
  • public health
  • mental health
  • ulcerative colitis
  • health information
  • social media